Skip to main content
SpringerLink
Log in

Androgen Receptor Directed Therapies in Castration-Resistant Metastatic Prostate Cancer

  • Genitourinary Cancer (MJ Morris, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Recent results of phase III randomized studies confirm that targeting the androgen receptor (AR)—through inhibition of androgen synthesis or through AR targeting directly—can improve survival for patients with metastatic castration-resistant prostate cancer (mCRPC), a condition previously considered to be “refractory” to further hormonal manipulation. These data validate in the clinical setting much of the scientific work of the previous decade that has demonstrated the extent of and mechanisms behind retained AR signaling in advanced prostate cancer. The convergence of these observations effectively changes the perspective with which androgen deprivation is utilized in prostate cancer, and forms the basis for further expansion of systemic therapy in the disease. In this review, the rationale for and clinical results with these new therapies will be discussed as will the future directions required to fully leverage these therapeutic modalities to the maximum clinical benefit for patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References and Recommended Readings

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Huggins C, Hodges CV. Studies on prostatic cancer, effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–7.

    CAS  Google Scholar 

  2. Crawford ED, Eisenberger MA, McLoed DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321:419–24.

    Article  PubMed  CAS  Google Scholar 

  3. Dijkman GA, Janknegt RA, De Reijke THM, et al. Long-term efficacy and safety of nilutamide plus castration in advanced stage prostate cancer, and the significance of early prostate specific antigen normalization. J Urol. 1997;158:160–3.

    Article  PubMed  CAS  Google Scholar 

  4. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036–42.

    Article  PubMed  CAS  Google Scholar 

  5. Edwards J, Krishna NS, Grigor KM, et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer. 2003;89:552–6.

    Article  PubMed  CAS  Google Scholar 

  6. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol. 2004;164:217–27.

    Article  PubMed  CAS  Google Scholar 

  7. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006;66:2815–25.

    Article  PubMed  CAS  Google Scholar 

  8. Taplin ME, Bubley GJ, Ko YJ, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 1999;59:2511–5.

    PubMed  CAS  Google Scholar 

  9. Sun S, Sprenger CC, Vessella RL, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010;120:2715–30.

    Article  PubMed  CAS  Google Scholar 

  10. Guo Z, Yang X, Sun F, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009;69:2305–13.

    Article  PubMed  CAS  Google Scholar 

  11. Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol. 1993;11:2167–72.

    PubMed  CAS  Google Scholar 

  12. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.

    Article  PubMed  CAS  Google Scholar 

  13. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363:411–22

  14. de Bono JS, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 376:1147–54

  15. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.

    Article  PubMed  Google Scholar 

  16. Cai C, Chen S, Ng P, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011;71:6503–13.

    Article  PubMed  CAS  Google Scholar 

  17. Pont A, Williams PL, Azhar S, et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med. 1982;142:2137–40.

    Article  PubMed  CAS  Google Scholar 

  18. De Coster R, Caers I, Coene MC, et al. Effects of high dose ketoconazole therapy on the main plasma testicular and adrenal steroids in previously untreated prostatic cancer patients. Clin Endocrinol (Oxf). 1986;24:657–64.

    Article  Google Scholar 

  19. Haidar S, Ehmer PB, Barassin S, et al. Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. J Steroid Biochem Mol Biol. 2003;84:555–62.

    Article  PubMed  CAS  Google Scholar 

  20. Small EJ, Baron AD, Fippin L, et al. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol. 1997;157:1204–7.

    Article  PubMed  CAS  Google Scholar 

  21. Small E, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004;22:1025–33.

    Article  PubMed  CAS  Google Scholar 

  22. Barrie SE, Potter GA, Goddard PM, et al. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol. 1994;50:267–73.

    Article  PubMed  CAS  Google Scholar 

  23. Potter GA, Barrie SE, Jarman M, et al. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem. 1995;38:2463–71.

    Article  PubMed  CAS  Google Scholar 

  24. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563–71.

    Article  PubMed  CAS  Google Scholar 

  25. Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010;28:1481–8.

    Article  PubMed  CAS  Google Scholar 

  26. Attard G, Reid AH, A’Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27:3742–8.

    Article  PubMed  CAS  Google Scholar 

  27. Matsunaga N, Kaku T, Itoh F, et al. C17,20-lyase inhibitors I. Structure-based de novo design and SAR study of C17,20-lyase inhibitors. Bioorg Med Chem. 2004;12:2251–73.

    Article  PubMed  CAS  Google Scholar 

  28. Dreicer R, Agus DB, MacVicar GR, et al. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: A phase I/II, open-label study. J Clin Oncol. 2010;28:15s.

    Google Scholar 

  29. Agus DB, Stadler WM, Shevrin D, et al. Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): updated data from a phase 1/2 study. Chicago: American Society of Clinical Oncology; 2011. Phase I/II study demonstrating the clinical efficacy of orteronel, including in a group of patients who did not receive prednisone. The rate of adverse events related to secondary mineralocorticoid excess was low, lending support to the hypothesis that orteronel may be administered without steroids. This remains to be seen.

    Google Scholar 

  30. Vasaitis T, Belosay A, Schayowitz A, et al. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther. 2008;7:2348–57.

    Article  PubMed  CAS  Google Scholar 

  31. Fowler JE, Pandey P, Seaver LE, et al. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol. 1995;154:448–53.

    Article  PubMed  Google Scholar 

  32. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome: experience in a large cohort of unselected patients with advanced prostate cancer. Cancer. 1995;76:1428–34.

    Article  PubMed  CAS  Google Scholar 

  33. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33–9.

    Article  PubMed  Google Scholar 

  34. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787–90.

    Article  PubMed  CAS  Google Scholar 

  35. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;375:1437–46.

    Article  PubMed  CAS  Google Scholar 

  36. Scher, HI: Effect of MDV3100 an androgen receptor signaling inhibitor (ARSI), on overal survival in patient with prostate cancer postdocetaxel: results from the phase III AFFIRM study. J Clin Oncol. 2012;30(suppl 5, abstr LBA1). After planned interim analysis at 520 deaths, the study was unblinded and patient on placebo were offered treatment with MDV3100 based on the significant improvement in overall survival in patient treated with MDV3100.

  37. Sawyers CL: New Insights into the Prostate Cancer Genome and Therapeutic Implications, State of the Science Report. Presented at the 17th Annual Prostate Cancer Foundation Scientific Retreat, Washington D.C., 2010

  38. Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009;69:16–22.

    Article  PubMed  CAS  Google Scholar 

  39. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11–22.

    Article  PubMed  CAS  Google Scholar 

  40. Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer. Cancer Cell. 2011;19:575–86.

    Article  PubMed  CAS  Google Scholar 

  41. Darshan MS, Loftus MS, Thadani-Mulero M, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 2011;71:6019–29.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, San Francisco, CA, 94115, USA

    Won Kim MD & Charles J Ryan MD

Authors
  1. Won Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles J Ryan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles J Ryan MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, W., Ryan, C.J. Androgen Receptor Directed Therapies in Castration-Resistant Metastatic Prostate Cancer. Curr. Treat. Options in Oncol. 13, 189–200 (2012). https://doi.org/10.1007/s11864-012-0188-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-012-0188-2

Keywords

Search

Navigation